Deutsche Bank AG purchased a new position in Savara Inc. (NASDAQ:SVRA - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 864,956 shares of the company's stock, valued at approximately $5,328,000. Deutsche Bank AG owned about 0.42% of Savara as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also modified their holdings of SVRA. VR Adviser LLC raised its stake in Savara by 8.4% during the fourth quarter. VR Adviser LLC now owns 13,740,375 shares of the company's stock worth $82,854,000 after acquiring an additional 1,059,332 shares during the period. Vanguard Group Inc. boosted its stake in Savara by 20.8% in the fourth quarter. Vanguard Group Inc. now owns 10,041,647 shares of the company's stock valued at $60,551,000 after acquiring an additional 1,728,453 shares during the period. Nantahala Capital Management LLC boosted its stake in Savara by 5.4% in the third quarter. Nantahala Capital Management LLC now owns 8,775,375 shares of the company's stock valued at $31,328,000 after acquiring an additional 450,000 shares during the period. Polar Capital Holdings Plc bought a new position in shares of Savara during the fourth quarter valued at approximately $50,086,000. Finally, RTW Investments LP bought a new position in shares of Savara during the fourth quarter valued at approximately $35,893,000. Institutional investors own 87.93% of the company's stock.
Savara Price Performance
NASDAQ SVRA opened at $5.56 on Tuesday. Savara Inc. has a 52 week low of $3.08 and a 52 week high of $7.01. The company has a current ratio of 10.13, a quick ratio of 10.13 and a debt-to-equity ratio of 0.21. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -9.59 and a beta of 0.29. The company has a 50-day moving average price of $5.70 and a two-hundred day moving average price of $5.47.
Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Analysts forecast that Savara Inc. will post -0.62 EPS for the current year.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on SVRA. Wall Street Zen cut Savara from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Savara in a research report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Savara currently has a consensus rating of "Moderate Buy" and an average price target of $10.14.
Get Our Latest Report on Savara
Savara Profile
(
Free Report)
Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.
The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.
Recommended Stories
Want to see what other hedge funds are holding SVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Savara Inc. (NASDAQ:SVRA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
